Therapeutic Drug Monitoring Market: Growth, Trends, Opportunities, and Future Outlook

The global Therapeutic Drug Monitoring Market is experiencing significant growth as healthcare providers increasingly focus on personalized treatment, medication safety, and optimized drug dosing. According to Kings Research, the global market was valued at USD 1,897.3 million in 2023 and is projected to grow from USD 2,032.9 million in 2024 to USD 3,575.6 million by 2031, registering a CAGR of 8.40% during 2024–2031.

Therapeutic drug monitoring (TDM) is particularly important for medicines that have a narrow therapeutic range, significant variability in patient response, or a high risk of toxicity. By measuring drug concentrations in biological samples, healthcare professionals can determine whether a patient is receiving an appropriate dose and make adjustments when necessary.

The increasing prevalence of chronic diseases, growing healthcare expenditure, advances in diagnostic technologies, and the rising adoption of precision medicine are creating favorable conditions for the expansion of the therapeutic drug monitoring industry.

What Is Therapeutic Drug Monitoring?

Therapeutic drug monitoring is a clinical practice that involves measuring specific drug concentrations in a patient's bloodstream at designated intervals. The objective is to maintain drug concentrations within a therapeutic range that provides the desired clinical effect while minimizing toxicity and adverse reactions.

TDM is especially valuable for drugs whose pharmacokinetics vary considerably between individuals. Factors such as age, kidney function, liver function, genetics, drug interactions, and adherence can influence how medicines are absorbed, distributed, metabolized, and eliminated.

Common drug classes monitored through TDM include antiepileptic drugs, antibiotics, immunosuppressants, psychiatric medications, and analgesics.

Key Growth Drivers of the Therapeutic Drug Monitoring Market

Rising Prevalence of Chronic Diseases

The increasing prevalence of chronic diseases is a major factor driving demand for therapeutic drug monitoring. Conditions such as cancer, cardiovascular diseases, neurological disorders, autoimmune diseases, and other long-term illnesses frequently require prolonged medication regimens.

Long-term treatment increases the importance of maintaining appropriate drug concentrations. TDM enables clinicians to monitor treatment response and modify dosage when required, supporting safer and more effective patient management.

According to the World Health Organization, cardiovascular diseases remain the leading cause of noncommunicable-disease deaths globally, accounting for approximately 17.9 million deaths annually. The high burden of chronic diseases creates continued demand for medication-management strategies, including therapeutic drug monitoring.

Growing Adoption of Personalized Medicine

Personalized medicine is transforming healthcare by shifting treatment decisions from generalized approaches toward patient-specific therapies. Therapeutic drug monitoring supports this transition by providing quantitative information that clinicians can use to individualize medication doses.

Patients receiving the same drug and nominal dose can have substantially different drug concentrations because of differences in metabolism, genetics, age, organ function, and interactions with other medicines. TDM helps clinicians account for these differences and improve treatment optimization.

Increasing Healthcare Expenditure

Growing healthcare spending is enabling hospitals, diagnostic laboratories, and research institutions to invest in sophisticated analytical instruments and diagnostic infrastructure.

The availability of advanced laboratory equipment is expanding the ability of healthcare facilities to perform drug-level testing with greater speed and precision. This is particularly important in hospitals managing complex patients who require close medication monitoring.

Advances in Diagnostic Technologies

Technological advancements in analytical chemistry are improving the sensitivity, specificity, and efficiency of therapeutic drug monitoring.

High-performance liquid chromatography (HPLC), liquid chromatography-mass spectrometry (LC-MS), and other advanced analytical methods allow laboratories to identify and quantify drug compounds in complex biological samples.

These technologies can provide more accurate measurements and support clinical decisions involving dose optimization.

Major Trends in the Therapeutic Drug Monitoring Market

Increasing Use of Mass Spectrometry

Mass spectrometry is becoming an increasingly important analytical technology in therapeutic drug monitoring. It enables highly specific molecular identification and quantitative analysis of pharmaceutical compounds.

When combined with liquid chromatography, mass spectrometry can provide accurate analysis of multiple compounds in biological samples. As laboratories seek greater analytical performance, adoption of LC-MS-based testing is expected to create opportunities for market participants.

Growth of Point-of-Care Testing

Point-of-care testing is another important trend influencing the TDM market. Conventional laboratory testing can require sample transportation and processing time, while point-of-care solutions can potentially provide drug-level information closer to the patient.

Portable testing technologies may be particularly useful in settings where rapid clinical decisions are required. The growing demand for convenient, real-time diagnostic information is encouraging companies to develop compact and user-friendly TDM platforms.

For example, THERADIAG launched ez-Track1 in May 2022 as a point-of-care testing solution designed for therapeutic drug monitoring.

Digitalization of Laboratory Operations

Digital laboratory systems are increasingly being used to improve data management, workflow efficiency, and analytical interpretation.

In 2023, Lifespin introduced software designed for therapeutic drug monitoring laboratories. The platform was intended to improve laboratory accuracy, efficiency, productivity, and data-management capabilities.

The integration of laboratory software with electronic health records and clinical decision-support systems could further strengthen the role of TDM in personalized healthcare.

Therapeutic Drug Monitoring Market Segmentation

According to Kings Research, the global therapeutic drug monitoring market is segmented by product, technology, drug class, end-user, and region.

By Product

The market is divided into:

• Consumables
• Equipment
• Immunoassay Analyzers
• Chromatography & MS Equipment
• Others

The consumables segment dominated the market in 2023, generating approximately USD 1,182.7 million. Reagents, test kits, disposables, and other consumables are required for routine testing and laboratory operations, resulting in recurring demand.

The increasing adoption of precision diagnostics and specialized testing is expected to support continued growth in this segment.

By Technology

The technology segment includes:

• Immunoassays
• Chemiluminescence Immunoassays
• Colorimetric Immunoassays
• Fluorescence Immunoassays
• Others
• Chromatography
• LC-MS
• GC-MS

Immunoassays remain important because of their established use in clinical laboratories, while chromatography and mass spectrometry are gaining importance because of their analytical accuracy and ability to detect multiple compounds.

By Drug Class

The market is segmented into:

• Antiepileptic Drugs
• Antibiotics
• Immunosuppressants
• Psychiatric Drugs
• Analgesics
• Others

The antiepileptic drugs segment held the largest share in 2023 at 24.83%. The segment is supported by the global burden of epilepsy and the need to maintain appropriate drug concentrations during treatment.

The World Health Organization estimates that approximately 50 million people worldwide are affected by epilepsy. Appropriate diagnosis and treatment can enable many patients to achieve effective seizure control, reinforcing the importance of optimized medication management.

By End User

The end-user segment comprises:

• Hospital Laboratories
• Commercial and Private Laboratories
• Research & Academic Laboratories

Hospital laboratories are expected to remain a major end-user category. Kings Research projects this segment to reach USD 1,875.4 million by 2031.

Hospitals have access to sophisticated diagnostic infrastructure and manage patients with complex medication requirements. The integration of laboratory systems with electronic health records can further improve the usefulness of TDM results for clinical decision-making.

Regional Analysis

North America

North America held the largest share of the global therapeutic drug monitoring market in 2023, accounting for approximately 39.82%, equivalent to USD 755.6 million.

The region benefits from advanced healthcare infrastructure, significant research and development investments, a strong presence of market participants, and high adoption of sophisticated diagnostic technologies.

The United States represents a particularly important market because of its extensive hospital and laboratory infrastructure and growing demand for personalized healthcare.

Asia-Pacific

Asia-Pacific is expected to experience strong growth during the forecast period, with Kings Research projecting a CAGR of 9.41% between 2024 and 2031.

Increasing healthcare expenditure, expanding pharmaceutical industries, rising awareness of personalized medicine, and improvements in diagnostic infrastructure are supporting market development.

Countries including China, Japan, India, and South Korea are expected to offer significant opportunities as healthcare providers increasingly adopt advanced diagnostic technologies.

Europe

Europe represents an important market due to its established healthcare systems, emphasis on patient safety, and strong pharmaceutical and biotechnology industries.

The growing focus on precision medicine and evidence-based treatment strategies is expected to increase demand for technologies that can help clinicians optimize drug dosing.

Middle East & Africa

The Middle East and Africa market is supported by gradual improvements in healthcare infrastructure and growing investment in diagnostic capabilities.

The expansion of hospital laboratories and increasing awareness of advanced clinical testing can create opportunities for therapeutic drug monitoring providers, particularly in countries investing heavily in modern healthcare systems.

Latin America

Latin America is also expected to witness gradual adoption of TDM solutions. Rising healthcare expenditure, increasing chronic disease prevalence, and improvements in diagnostic laboratory infrastructure can support demand for drug-monitoring technologies.

Major Challenges in the Therapeutic Drug Monitoring Market

High Cost of Advanced Analytical Equipment

The high cost of advanced analytical instruments can limit adoption, particularly among smaller hospitals and laboratories. Technologies such as mass spectrometry require significant capital investment as well as specialized infrastructure.

Maintenance and calibration expenses can further increase the total cost of ownership.

Requirement for Skilled Professionals

TDM procedures can require specialized knowledge in analytical chemistry, laboratory medicine, pharmacology, and clinical interpretation.

The shortage of trained professionals can therefore create challenges for healthcare facilities seeking to establish or expand TDM capabilities.

Regulatory and Quality-Control Requirements

Therapeutic drug monitoring involves clinical diagnostic testing, making accuracy and reliability essential. Laboratories must maintain appropriate quality-control procedures and comply with applicable regulatory requirements.

Strict validation, calibration, quality assurance, and documentation requirements can increase operational complexity.

Competitive Landscape

The global therapeutic drug monitoring market is relatively fragmented, with major companies competing through product development, partnerships, acquisitions, technological innovation, and geographic expansion.

Key companies identified by Kings Research include:

• Abbott Laboratories
• bioMérieux SA
• F. Hoffmann-La Roche AG
• Siemens Healthineers
• Thermo Fisher Scientific Inc.
• Danaher Corporation
• BÜHLMANN Laboratories AG
• Sekisui Medical Co., Ltd.
• Randox Laboratories Ltd.
• Bio-Rad Laboratories, Inc.

Companies are increasingly focusing on improving testing accuracy, reducing turnaround times, developing automated workflows, and integrating diagnostic technologies with digital healthcare platforms.

Recent Industry Development

In October 2023, ProciseDx announced that it had received FDA clearance for therapeutic drug monitoring tests designed to measure biologic drugs including Humira, Remicade, and their biosimilars. The development represented an expansion of TDM beyond traditional small-molecule drugs and demonstrated the growing role of monitoring in biologic therapies.

Such developments could broaden the addressable market by supporting therapeutic monitoring for increasingly complex pharmaceutical treatments.

Future Outlook

The future of the Therapeutic Drug Monitoring Market is closely linked to the broader transformation toward precision medicine and patient-centered healthcare.

Kings Research projects the market to reach USD 3,575.6 million by 2031, increasing from USD 2,032.9 million in 2024 at a CAGR of 8.40%.

Several factors are expected to shape future market development:

• Increasing prevalence of chronic diseases
• Growing adoption of personalized medicine
• Expansion of biologic and complex therapies
• Increased healthcare expenditure
• Development of rapid point-of-care testing
• Greater adoption of LC-MS and other advanced analytical methods
• Digitalization of laboratory operations
• Integration with electronic health records
• Increasing demand for medication safety
• Expansion of diagnostic infrastructure in emerging economies

Point-of-care technologies are likely to become particularly important because faster access to drug-concentration information can support more timely clinical decisions.

Conclusion

The Therapeutic Drug Monitoring Market is becoming increasingly important as healthcare systems move toward personalized, data-driven, and safer medication management. TDM provides clinicians with objective information about drug concentrations, allowing treatment regimens to be adjusted according to individual patient requirements.

The global market is projected to grow from USD 1,897.3 million in 2023 to USD 3,575.6 million by 2031, reflecting an 8.40% CAGR during the forecast period.

Technological innovation, particularly in mass spectrometry, chromatography, point-of-care diagnostics, and laboratory software, is expected to remain a major source of market opportunity. At the same time, industry participants will need to address equipment costs, skilled-labor requirements, regulatory complexity, and accessibility.

As personalized medicine becomes more widely adopted, therapeutic drug monitoring is expected to play a growing role in improving medication efficacy, minimizing toxicity, and supporting better patient outcomes worldwide.